{"disease":{"id":"uveitis","name":"Uveitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":23,"pipeline_drug_count":0,"trial_count":4},"drugs":{"marketed":[{"drug_id":"abrilada","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"abrilada","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"infliximab-infliximab-biosimilar-3","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infliximab [infliximab biosimilar 3]","generic_name":"infliximab-infliximab-biosimilar-3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor-alpha (TNF-alpha)","drug_class":"monoclonal antibody","quality_score":10,"revenue":"646","mechanism":"Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions."},{"drug_id":"loteprednol-etabonate-and-tobramycin","indication_name":"Chronic anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"loteprednol etabonate and tobramycin","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial [EPC]","quality_score":31,"revenue":null,"mechanism":null},{"drug_id":"drug-abatacept","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug: \"Abatacept\"","company_name":"Shinshu University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"drug-abatacept","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug: \"Abatacept\"","company_name":"Shinshu University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fusidic-acid","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"loteprednol-etabonate","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotemax","generic_name":"LOTEPREDNOL ETABONATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"loteprednol-etabonate","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotemax","generic_name":"LOTEPREDNOL ETABONATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tobramycin","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"tobramycin","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"fluorometholone","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fml","generic_name":"FLUOROMETHOLONE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sulfacetamide","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Klaron","generic_name":"SULFACETAMIDE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"Sulfonamide Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"medrysone","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrifar","generic_name":"MEDRYSONE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"lotemax","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lotemax","company_name":"Tufts Medical Center","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lotemax","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lotemax","company_name":"Tufts Medical Center","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Non-infectious Posterior Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"adalimumab","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"adalimumab","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"hydrocortisone","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"neomycin","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"NEOMYCIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 1","drug_class":"Aminoglycoside Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"adalimumab-adbm","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"adalimumab-adbm","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Sympathetic uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"polymyxin-b","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"POLYMYXIN B","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"fluorometholone-acetate","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flarex","generic_name":"FLUOROMETHOLONE ACETATE","company_name":"Harrow Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"homatropine","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Homatropin","generic_name":"homatropine","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"benzalkonium","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzododecinium","generic_name":"BENZALKONIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"benzalkonium","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"loteprednol","indication_name":"acute anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Loteprednol Etabonate","generic_name":"LOTEPREDNOL","company_name":"Bausch And Lomb","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"cortisol","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Sympathetic uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Sympathetic uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"humira","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"humira","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Diffuse posterior uveitis and choroiditis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"scopolamin","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"scopolamin","company_name":"University Hospital, Angers","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone-phosphate","indication_name":"Diffuse posterior uveitis and choroiditis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"adalimumab-aqvh","indication_name":"Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"YUSIMRY","generic_name":"ADALIMUMAB-AQVH","company_name":"COHERUS BIOSCIENCES INC","drug_phase":"marketed","molecular_target":"","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":49,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00116090","title":"Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":6300,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT03753893","title":"Ocular Manifestations in Rheumatic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT00001310","title":"Tissue Studies of Human Eye Diseases","phase":"","overall_status":"TERMINATED","enrollment_count":3833,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT05200715","title":"AutoInflammatory Disease Alliance Registry (AIDA)","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"University of Siena","has_results":false},{"nct_id":"NCT00001734","title":"Screening for NEI Clinical Studies","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT00539370","title":"Human Samples and Data Repository","phase":"","overall_status":"TERMINATED","enrollment_count":1862,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT06686641","title":"Incidence of Macular Edema in a Uveitis Population","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1550,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT03899922","title":"Monitoring Drug-induced Uveitis","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT03646890","title":"Epidemiology and Clinical Features of Uveitis in a Tertiary Referral","phase":"","overall_status":"COMPLETED","enrollment_count":985,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT03877575","title":"Lyon Uveitis Study","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT00647439","title":"Genetics and Markers of Degenerative and Inflammatory Eye Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":609,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT05153057","title":"Birdshot Chorioretinopathy : Prospective Follow-up and Immunogenetic Studies(CO-BIRD)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05727540","title":"The Cohort Study of Uveitis Patients","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT05130385","title":"High Resolution Optical Coherence Tomography","phase":"","overall_status":"UNKNOWN","enrollment_count":550,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT02466217","title":"Phenomics in Autoimmune and Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":537,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06250881","title":"Analysis of Ocular Complications of AIDS Patients in Ophthalmic Consultation","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT04705103","title":"Development of AI Model for Uveitis Progression and Prognosis","phase":"","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01148225","title":"A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":424,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06431373","title":"A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":371,"lead_sponsor_name":"Priovant Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02656381","title":"Uveitis/Intraocular Inflammatory Disease Biobank (iBank)","phase":"","overall_status":"COMPLETED","enrollment_count":343,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT06102408","title":"Relevance and Efficiency of SecOnd Line Workup for Uveitis","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT04193020","title":"Acute and Chronic Inflammatory Disease, Lifestyle and Treatment Response","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Wroclaw Medical University","has_results":false},{"nct_id":"NCT06273748","title":"RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age","phase":"","overall_status":"RECRUITING","enrollment_count":290,"lead_sponsor_name":"Meyer Children's Hospital IRCCS","has_results":false},{"nct_id":"NCT02916017","title":"HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis","phase":"","overall_status":"COMPLETED","enrollment_count":259,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02517619","title":"Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Eyegate Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02951975","title":"Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye","phase":"","overall_status":"TERMINATED","enrollment_count":246,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT03173144","title":"Chronic Inflammatory Disease, Lifestyle and Treatment Response","phase":"","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT03828019","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":227,"lead_sponsor_name":"JHSPH Center for Clinical Trials","has_results":true},{"nct_id":"NCT02819206","title":"Microbiological Diagnosis of Infectious Uveitis to Pathogenic Fastidious Germs","phase":"NA","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT07262437","title":"Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"University of Milan","has_results":false},{"nct_id":"NCT04101604","title":"Biomarkers of Common Eye Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":220,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04018599","title":"Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"Fresenius Kabi SwissBioSim GmbH","has_results":false},{"nct_id":"NCT07176130","title":"Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Singapore National Eye Centre","has_results":false},{"nct_id":"NCT02623426","title":"Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":194,"lead_sponsor_name":"JHSPH Center for Clinical Trials","has_results":true},{"nct_id":"NCT04798755","title":"Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":192,"lead_sponsor_name":"Hospital San Carlos, Madrid","has_results":false},{"nct_id":"NCT02374060","title":"PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"JHSPH Center for Clinical Trials","has_results":true},{"nct_id":"NCT02595398","title":"Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Clearside Biomedical, Inc.","has_results":true},{"nct_id":"NCT03339102","title":"Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients","phase":"","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03155243","title":"Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02746991","title":"Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"EyePoint Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07136805","title":"A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":152,"lead_sponsor_name":"VivaVision Biotech, Inc","has_results":false},{"nct_id":"NCT00331331","title":"The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease","phase":"","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT03711929","title":"LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":145,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT05042609","title":"A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Tarsier Pharma","has_results":false},{"nct_id":"NCT03525028","title":"A Clinical Trial of Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":138,"lead_sponsor_name":"Tianjin Medical University","has_results":false},{"nct_id":"NCT01859299","title":"Intestinal Bacteria and Ocular Inflammatory Disease","phase":"","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT05105347","title":"Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":130,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT01694186","title":"Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"EyePoint Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06310837","title":"Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":128,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT03131154","title":"SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Aldeyra Therapeutics, Inc.","has_results":true}],"total":50},"guidelines":[{"drug_id":"adalimumab","guideline_body":"FDA label","recommendation":"Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.","line_of_therapy":"1L|2L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}